Log in

NASDAQ:FGEN - FibroGen Stock Price, Forecast & News

$45.58
+1.07 (+2.40 %)
(As of 02/17/2020 01:28 AM ET)
Add
Today's Range
$43.82
Now: $45.58
$46.08
50-Day Range
$41.61
MA: $43.35
$45.96
52-Week Range
$32.33
Now: $45.58
$61.23
Volume552,179 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio116.87
Dividend YieldN/A
BetaN/A
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:FGEN
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees461
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.


FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) posted its quarterly earnings data on Monday, November, 11th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.02. The biopharmaceutical company had revenue of $33.17 million for the quarter, compared to analysts' expectations of $31.61 million. FibroGen's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.50) earnings per share. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

4 equities research analysts have issued 12 month target prices for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they anticipate FibroGen's share price to reach $52.33 in the next year. This suggests a possible upside of 14.8% from the stock's current price. View Analyst Price Targets for FibroGen.

What is the consensus analysts' recommendation for FibroGen?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.

Has FibroGen been receiving favorable news coverage?

Headlines about FGEN stock have been trending somewhat positive on Monday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FibroGen earned a news impact score of 2.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for FibroGen.

Are investors shorting FibroGen?

FibroGen saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 5,580,000 shares, an increase of 10.3% from the January 15th total of 5,060,000 shares. Based on an average daily volume of 825,000 shares, the days-to-cover ratio is currently 6.8 days. Currently, 7.2% of the company's stock are sold short. View FibroGen's Current Options Chain.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Transocean (RIG).

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
  • Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 57)
  • Mr. Julian N. Stern, Sec. (Age 94)
  • Dr. Barry A. Berkowitz, Founder

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (10.81%), State Street Corp (3.02%), Farallon Capital Management LLC (1.55%), First Trust Advisors LP (1.50%), Bank of New York Mellon Corp (1.31%) and Goldman Sachs Group Inc. (1.20%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., State Street Corp, Handelsbanken Fonder AB, Strs Ohio, Rafferty Asset Management LLC, Citigroup Inc., Bank of America Corp DE and Bank of Montreal Can. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo and Thomas B Neff. View Insider Buying and Selling for FibroGen.

Which institutional investors are buying FibroGen stock?

FGEN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Farallon Capital Management LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Credit Suisse AG, AQR Capital Management LLC, Assenagon Asset Management S.A. and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $45.58.


MarketBeat Community Rating for FibroGen (NASDAQ FGEN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Gap Down Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel